"Aromatase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
| Descriptor ID |
D047072
|
| MeSH Number(s) |
D27.505.519.389.870.300 D27.505.696.399.450.327.149 D27.505.696.399.450.855.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aromatase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Aromatase Inhibitors".
This graph shows the total number of publications written about "Aromatase Inhibitors" by people in this website by year, and whether "Aromatase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 2 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aromatase Inhibitors" by people in Profiles.
-
Factors associated with longer endocrine therapy use by South Carolina Medicaid-insured breast cancer survivors. J Oncol Pharm Pract. 2020 Jan; 26(1):36-42.
-
Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women. Breast Cancer Res Treat. 2018 Oct; 171(3):759-765.
-
Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 2018 08; 41:59-65.
-
Genomic risk prediction of aromatase inhibitor-related arthralgia in patients with breast cancer using a novel machine-learning algorithm. Cancer Med. 2018 01; 7(1):240-253.
-
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Apr 01; 35(10):1061-1069.
-
Drugs that may harm bone: Mitigating the risk. Cleve Clin J Med. 2016 Apr; 83(4):281-8.
-
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila). 2011 Dec; 4(12):1993-2001.
-
Aromatase inhibition causes increased amplitude, but not frequency, of hypothalamic-pituitary output in normal women. Fertil Steril. 2011 May; 95(6):2063-6.
-
Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res. 2011 Feb 01; 17(3):560-8.
-
Predictors of yoga use among patients with breast cancer. Explore (NY). 2010 Nov-Dec; 6(6):359-63.